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*IDIBAPS, {Institut de Pneumologia i Cirurgia Tora`cica, {Servei d’Oto-rino-laringologia, Hospital Clı´nic,
Departament de Medicina, Universitat de Barcelona, Spain
Nasal epithelial cells maintain eosinophil survival by secreting granulocyte/macrophage colony-stimulating factor
(GM-CSF). Corticosteroids antagonize eosinophil viability induced by GM-CSF. We investigated the eect of
topical corticosteroids and nedocromil sodium on the release of GM-CSF from nasal polyp epithelial cells.
Epithelial cells were obtained from 19 patients undergoing nasal polypectomy and cultured. After reaching
confluence, cultured cells were stimulated with 10% foetal calf serum in the absence and presence of four topical
corticosteroids and nedocromil sodium for 48 h. GM-CSF was measured by enzyme linked immunosorbent assay
(ELISA).
Fluticasone propionate was the most potent inhibitor of GM-CSF release (IC25=46 pM) closely followed by
budesonide (IC25=4 nM), beclomethasone dipropionate (IC25=40 nM) and triamcinolone acetonide (IC25=
75 nM). Nedocromil sodium had no eect on GM-CSF release.
We conclude that the eect of topical steroids on reducing eosinophil infiltration in nasal polyps may be due in
part to downregulation, among other cytokines, of epithelial GM-CSF production which prolongs eosinophil
viability. Quantitatively, fluticasone propionate inhibited GM-CSF production more potently than budesonide,
beclomethasone dipropionate and triamcinolone acetonide.
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There is evidence that the eosinophil infiltrate in nasal
polyps is the consequence of both preferential recruitment
of eosinophils (1,2) and prolonged eosinophil survival
within the inflamed microenvironment (3,4).
Epithelial cells synthesize a number of growth factors
and cytokines (5). Among other potential cytokines, nasal
epithelial cells maintain eosinophil survival by secreting
granulocyte/macrophage colony-stimulating factor (GM-
CSF) (2,3,4). Corticosteroids antagonize the viability-
sustaining eect of GM-CSF (3,4).
Topical corticosteroids are the recommended treatment
for patients with nasal polyposis (6). Nasal polyp epithelial
cells are the first line target for topical corticosteroids. In
this study we focused on the eect of topical corticosteroids
on GM-CSF because of the important role of this cytokine
in eosinophil survival. We hypothesize that topical corti-Received 29 March 1999 and accepted in revised form 22
November 1999.
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inhibit the release of GM-CSF.
Methods
SUBJECTS
Nasal polyps were obtained from 19 patients (12 men, seven
women), aged 502 years, undergoing nasal polypectomy.
Seventeen patients (90%) were on intranasal or oral
corticosteroids at the time polypectomy was carried out.
The study was approved by the Ethics Committee of our
Institution.
EPITHELIAL CELL CULTURE
Transport of nasal polyps, and isolation, characterization
and culture of epithelial cells, were carried out according to
a method previously described in detail (3). After reaching
confluence, cultured epithelial cells were incubated with
10% foetal calf serum (FCS, Flow laboratories) for 48 h in
the absence (control) and presence of budesonide (Astra,
Barcelona, Spain), fluticasone propionate (GlaxoWellcome,
Greenford, U.K.), beclomethasone dipropionate (Glaxo# 2000 HARCOURT PUBLISHERS LTD
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(Sigma, Spain) and nedocromil sodium (Fisons Ibe´rica,
Zaragoza, Spain). Dose-response curves were obtained
using concentrations from 1075 to 10 713 M.
GM-CSF PRODUCTION
GM-CSF concentration in the cell supernatants was
directly measured by a commercial enzymo-linked immu-
noassay using a ‘sandwich’ technique (Amersham Ibe´rica,
Spain). GM-CSF limit of detection was 4 pg/ml.
STATISTICAL ANALYSIS
Statistical evaluation was performed using the statistical
software package Statview II (Brainpower Inc. U.S.A.).
Results are expressed as meanstandard error of the
mean (SEM). A non-parametric test (Wilcoxon) was used forFIG. 1. Eect of topical corticosteroids on GM-CSF production f
10% increased GM-CSF production compared to media-treated
budesonide (BUD, n=7), beclomethasone dipropionate (BDP, n
dose-related inhibitory eect on FCS-induced GM-CSF release. V
test (**P5001, compared to media-treated cells; {P5005 andstatistical comparisons. A P5005 was considered statisti-
cally significant.
Results
Incubation of nasal polyp epithelial cells with 10% FCS
increased GM-CSF production in all experiments. At
baseline, the range of GM-CSF secretion was 26–89 pg
ml71 while after 10% FCS stimulation was 213–684 pg
ml71. FCS-induced release of GM-CSF was inhibited in a
dose-dependent manner by all four topical corticosteroids.
The inhibitory eects at 1075 M concentration were:
fluticasone propionate 71% (n=6, P5001), budesonide
58% (n=7, P5001), triamcinolone acetonide 42% (n=6,
P5002) and beclomethasone dipropionate 40% (n=6,
P5002), compared to positive control (10% FCS-treated
cells).
The minimal inhibitory concentration was 10711 M for
fluticasone and 1079 M for the other three corticosteroidsrom nasal polyp epithelial cells. Foetal calf serum (FCS) at
cells (control). Fluticasone propionate (FLU, n=6),
=6) and triamcinolone acetonide (TRI, n=6) caused a
alues are expressed as mean  SEM. Wilcoxon signed-rank
{{P5001, compared to FCS-treated cells).
TABLE 1. Inhibitory concentration of 25% (IC25) of topical
glucocorticoids and nedocromil sodium on GM-CSF
release induced by 10% fetal calf serum in cultured nasal
epithelial cells from nasal polyps
Anti-inflammatory drugs IC25
Fluticasone propionate 4635 pM}
Budesonide 42 nM{
Beclomethasone dipropionate 4017 nM{,}
Triamcinolone acetonide 7542 nM{,}
Nedocromil sodium 410 mM{
Wilcoxon Signed-Rank test (P5005): {compared to
fluticasone propionate; }compared to budesonide; {com-
pared to all glucocorticoids.
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significant inhibitory eect on GM-CSF production (10%,
n=6).
The potencies of the four corticosteroids on GM-CSF
release were compared. Table 1 shows the concentration of
corticosteroids producing 25% inhibition (IC25) of GM-
CSF release. We used IC25 instead of IC50 because most
corticosteroids did not reach 50% inhibition of the FCS-
induced GM-CSF production. Fluticasone propionate was
the most potent inhibitor of GM-CSF release, and was
significantly more potent than budesonide. Both fluticasone
propionate and budesonide were more potent than
beclomethasone dipropionate and triamcinolone acetonide.
All glucocorticoids were more potent than nedocromil
sodium.
Discussion
In this study we investigated the ability of several topical
corticosteroids and nedocromil sodium to modulate the
release of GM-CSF from nasal polyp epithelial cells in
vitro. However, the role of other cytokines produced by
epithelial and other cells, such as IL-5 and eotaxin, which
are potent eosinophil modulators should not be over-
looked.
The eect of topical corticosteroids on GM-CSF release
from nasal polyp epithelial cells has significance because
previous studies have shown that GM-CSF is responsible
for the induction of eosinophil survival (3,4). The chronic
presence of eosinophils in the respiratory mucosa results in
epithelial damage caused by cytotoxic products released by
degranulated cells. By reducing eosinophil viability, topical
corticosteroids contribute to reduce inflammation and
therefore facilitate mucosal damage repair. In this regard,
Kanai et al. (7) have shown the ecacy of budesonide in
reducing the number of activated eosinophil in nasal
polyps.
Our in vitro assay of topical corticosteroid potency tested
four topical corticosteroids for their capacity to inhibit therelease of GM-CSF from nasal polyp epithelial cells. The
comparison study showed that fluticasone propionate is the
most potent, followed by budesonide, beclomethasone
dipropionate and triamcinolone acetonide. Nedocromil
sodium had no eects on GM-CSF secretion.
The rank of potency found in our study closely agrees
with the rank order and relative potency obtained with the
same corticosteroids using the classical skin blanching
method. With this method the potency of fluticasone was
1200 (relative to the potency of dexamethasone, considered
1), budesonide 980, beclomethasone dipropionate 600 and
triamcinolone acetonide 330 (8).
Ideally, the validity of results obtained in in vitro studies
should be reproduced in in vivo surveys. Long-term
treatment with topical corticosteroids has been shown to
reduce symptoms of nasal polyposis and reduce polyp
recurrence following surgery (9–11). However, only a few
clinical trials have compared the clinical response of nasal
polyposis to dierent corticosteroids.
Two recent studies compared fluticasone propionate and
beclomethasone dipropionate in patients with severe poly-
posis (12,13). In the two studies there was evidence that
patients treated with fluticasone propionate responded
faster, and that the magnitude of the response was greater
than in patients receiving beclomethasone dipropionate.
Although our in vitro model may have some limitations in
relation to the presence of a constant steroid concentration,
the absence or decrease of metabolism, and the potential
lack of active metabolite formation, for instance beclo-
methasone 17-monopropionate from beclomethasone di-
propionate, the present in vitro model may be used as a
useful method to investigate and compare the potency of
topical anti-inflammatory drugs.
Although previous studies have shown that nedocromil
sodium significantly prevents stimulated GM-CSF produc-
tion in both cultured human bronchial (14) and nasal
epithelial cells (15), we could not find any significant eect
of this drug on GM-CSF release from cultured nasal polyp
epithelial cells. This finding suggests that the inflamed
microenvironment of nasal polyps had induced a relative
resistance to the pharmacological activity of nedocromil
sodium in epithelial cells. To our knowledge, nedocromil
sodium has not been used in the treatment of nasal
polyposis. However, our results predict poor clinical results
for this drug in the treatment of nasal polyps.
In summary, our study suggests that topical steroids may
reduce eosinophil infiltration in nasal polyps by down-
regulating the production of epithelial cell-derived cyto-
kines, such as GM-CSF, which prolongs eosinophil
viability. Quantitatively, the following rank of potency
was observed: fluticasone propionate 4 budesonide 4
beclomethasone dipropionate 4 triamcinolone acetonide
44 nedocromil sodium.
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